Adalimumab biosimilar (Fresenius Kabi)

阿达木单抗生物类似药 (Fresenius Kabi)

Report date: 2026/05/28 20:00:21

Base Information

Drug NameAdalimumab biosimilar (Fresenius Kabi)
Drug Alias Name阿达木单抗生物仿制药 (Fresenius Kabi)Recombinant human anti-tumour necrosis factor alpha (TNF-α) monoclonal antibody (Fresenius Kabi)Adalimumab-AACF重组抗肿瘤坏死因子-α全人源单抗 (Fresenius Kabi)重组抗TNFa全人单抗 (Fresenius Kabi) +[8] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPsoriasisUveitis +[11] 
Global Approved IndicationsPlaque psoriasisPsoriasisUveitis +[10] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2019/04/02
Country/TerritoryCzechiaBulgariaCanada +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMerck SeronoFresenius Kabi Ag
China Registration ClassN/A

Develop Information

Active CompaniesFresenius Kabi Usa LlcFresenius Kabi Deutschland Gmbh
Inactive CompaniesMerck KGaA, Darmstadt, GermanyFresenius Kabi Swissbiosim Gmbh
Active IndicationsPlaque psoriasisPsoriasisUveitis +[10] 
Inactive IndicationsPediatric Crohn's disease

Other Information

ATC CodeL04AB04
Related LinksN/A